SynthesisRevista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia2026
Preeclampsia Risk in Obese Pregnant Women without Diabetes Mellitus: a Meta-Analysis Comparing Metformin versus Control Group.
Synthesis in Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the impact of metformin on reducing the risk of pre-eclampsia in obese pregnant women without diabetes. Sources of Data: Following PRISMA guidelines, Scopus, Embase, PubMed (MEDLINE), Cochrane Database of Systematic Reviews, LILACS, SciElo, and Web of Science were searched for articles published between 2014 and April 2024. Search terms: ("Metformin" OR "Biguanide" OR "Glucophage" OR "dimethylbiguanide") AND ("pre-eclampsia" OR "preeclampsia") AND ("obese pregnant women" OR "obesity in pregnancy" OR "maternal obesity" OR "pregnancy" OR "obesity"). Study Selection: From 2022 studies identified, three randomized controlled trials comparing metformin with placebo or standard care in obese pregnant women without diabetes were included. Primary outcomes were pre-eclampsia incidence; secondary outcomes included gestational hypertension, gestational diabetes, preterm birth, cesarean delivery, postpartum hemorrhage, and NICU admission. Data collection: Data were extracted, and odds ratios (OR) with 95% confidence intervals (CI) were calculated. Heterogeneity was assessed using I Data Synthesis: Metformin did not significantly reduce PE risk (OR: 0.42; 95% CI: 0.10-1.68; p=0.22; I Conclusions: Metformin should not be routinely recommended for pre-eclampsia prevention in obese pregnant women without diabetes until robust evidence from further research supports its efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.